STOCK TITAN
  1. Home
  2. Sec-filings
  3. NKTR
  4. [SCHEDULE 13G/A] Nektar Therapeutics SEC Filing

[SCHEDULE 13G/A] Nektar Therapeutics SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock NKTR logo
Nektar Therapeutics

NASDAQ:NKTR

NKTR Rankings

#2629 Ranked by Market Cap
N/A Ranked by Dividends

NKTR Latest News

Sep 18, 2025
Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Sep 9, 2025
Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Sep 3, 2025
Nektar Therapeutics to Participate in Two Investor Conferences in September
Aug 7, 2025
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
Jul 31, 2025
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

NKTR Latest SEC Filings

Oct 1, 2025
[Form 4] NEKTAR THERAPEUTICS Insider Trading Activity
Oct 1, 2025
[Form 4] NEKTAR THERAPEUTICS Insider Trading Activity
Oct 1, 2025
[Form 4] NEKTAR THERAPEUTICS Insider Trading Activity
Oct 1, 2025
[Form 4] NEKTAR THERAPEUTICS Insider Trading Activity
Sep 18, 2025
[8-K] NEKTAR THERAPEUTICS Reports Material Event

NKTR Stock Data

1.10B
18.88M
0.74%
48.51%
5.87%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO